ENLV Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -369.06%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Compugen Ltd.'s return on equity of -51.8%.

Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 288.2%. Given that Enlivex Therapeutics Ltd. has higher upside potential than Compugen Ltd., analysts believe Enlivex Therapeutics Ltd. is more attractive than Compugen Ltd..

Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.

Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Compugen Ltd.'s net income of -$7M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 21.51x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Nasus Pharma has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of --. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Nasus Pharma's return on equity of --.

Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Enlivex Therapeutics Ltd. has higher upside potential than Nasus Pharma, analysts believe Enlivex Therapeutics Ltd. is more attractive than Nasus Pharma.

Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.

Enlivex Therapeutics Ltd. quarterly revenues are --, which are larger than Nasus Pharma quarterly revenues of --. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Nasus Pharma's net income of --. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

BiomX, Inc. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of --. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat BiomX, Inc.'s return on equity of -160.84%.

Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8264.78%. Given that BiomX, Inc. has higher upside potential than Enlivex Therapeutics Ltd., analysts believe BiomX, Inc. is more attractive than Enlivex Therapeutics Ltd..

Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.

Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.

Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -1940.51%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Pluri, Inc.'s return on equity of -5662.45%.

Enlivex Therapeutics Ltd. has a consensus price target of $7.00, signalling upside risk potential of 503.45%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 268.1%. Given that Enlivex Therapeutics Ltd. has higher upside potential than Pluri, Inc., analysts believe Enlivex Therapeutics Ltd. is more attractive than Pluri, Inc..

Enlivex Therapeutics Ltd. has a beta of 1.491, which suggesting that the stock is 49.132% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.476%.

Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $316K. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Pluri, Inc.'s net income of -$6.1M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 17.83x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.